| Sonstiges: |
- Nachgewiesen in: USPTO Patent Grants
- Sprachen: English
- Patent Number: 11175,291
- Publication Date: November 16, 2021
- Appl. No: 16/687726
- Application Filed: November 19, 2019
- Assignees: MeMed Diagnostics Ltd. (Tirat HaCarmel, IL)
- Claim: 1. A kit comprising antibodies, at least one of said antibodies is a monoclonal antibody, wherein a first antibody of said antibodies specifically binds to TNF-related apoptosis-inducing ligand (TRAIL) protein, a second antibody of said antibodies specifically binds to C-reactive protein (CRP) protein and a third antibody of said antibodies specifically binds to Interferon gamma-induced protein 10 (IP10) protein, wherein the kit does not comprise more than five additional antibodies which specifically bind to additional proteins which are differentially expressed in a statistically significant manner in subjects with a bacterial infection compared to subjects with a viral infection, each of said five additional antibodies targeting a different soluble protein.
- Claim: 2. A kit comprising antibodies immobilized on a solid support, wherein said antibodies comprise a first antibody that specifically binds to TRAIL protein, a second antibody that specifically binds to CRP protein, and a third antibody that specifically binds to IP10 protein, wherein the kit does not comprise more than five additional antibodies which specifically bind to additional proteins which are differentially expressed in a statistically significant manner in subjects with a bacterial infection compared to subjects with a viral infection, each of said five additional antibodies targeting a different soluble protein.
- Claim: 3. A kit comprising antibodies immobilized on a solid support, wherein said antibodies consist of a first antibody that specifically binds to TRAIL protein, a second antibody that specifically binds to CRP protein and a third antibody that specifically binds to IP10 protein.
- Claim: 4. The kit of claim 1 , further comprising: (i) an antibody that specifically binds to said TRAIL protein at an additional site as to the site to which said first antibody binds; (ii) an antibody that specifically binds to said CRP protein at an additional site as to the site to which said second antibody binds; and (iii) an antibody that specifically binds to said IP10 protein at an additional site as to the site to which said third antibody binds, wherein each of said antibodies of (i), (ii) and (iii) comprise a detectable label selected from the group consisting of a radioactive label, a fluorescent label, a chemiluminescent label, a colorimetric label and an enzyme.
- Claim: 5. The kit of claim 2 , further comprising: (i) an antibody that specifically binds to said TRAIL protein at an additional site as to the site to which said first antibody binds; (ii) an antibody that specifically binds to said CRP protein at an additional site as to the site to which said second antibody binds; and (iii) an antibody that specifically binds to said IP10 protein at an additional site as to the site to which said third antibody binds, wherein each of said antibodies of (i), (ii) and (iii) comprise a detectable label selected from the group consisting of a radioactive label, a fluorescent label, a chemiluminescent label, a colorimetric label and an enzyme.
- Claim: 6. The kit of claim 1 , wherein each of said first antibody, said second antibody and said third antibody are immobilized to a solid support.
- Claim: 7. The kit of claim 1 , wherein each of said first antibody, said second antibody and said third antibody are immobilized to a single solid support.
- Claim: 8. The kit of claim 2 , wherein each of said first antibody, said second antibody and said third antibody are immobilized to a single solid support.
- Claim: 9. The kit of claim 3 , wherein each of said first antibody, said second antibody and said third antibody are immobilized to a single solid support.
- Claim: 10. The kit of claim 4 , wherein said enzyme is horseradish peroxidase or alkaline phosphatase.
- Claim: 11. The kit of claim 5 , wherein said enzyme is horseradish peroxidase or alkaline phosphatase.
- Claim: 12. The kit of claim 1 , wherein the kit comprises antibodies that detect no more than three additional proteins which are differentially expressed in a statistically significant manner in subjects with a bacterial infection compared to subjects with a viral infection, each of said three additional antibodies targeting a different soluble protein.
- Claim: 13. The kit of claim 2 , wherein the kit comprises antibodies that detect no more than three additional proteins which are differentially expressed in a statistically significant manner in subjects with a bacterial infection compared to subjects with a viral infection, each of said three additional antibodies targeting a different soluble protein.
- Claim: 14. The kit of claim 2 , being used in a lateral flow immunoassay.
- Claim: 15. The kit of claim 3 , being used in a lateral flow immunoassay.
- Patent References Cited: 5639617 June 1997 Bohuon ; 5910421 June 1999 Small, Jr. et al. ; 6077665 June 2000 Welrich et al. ; 6136526 October 2000 Venge ; 6210661 April 2001 Enssle et al. ; 6709855 March 2004 Stanton et al. ; 6756483 June 2004 Bergmann et al. ; 6953435 October 2005 Kondo et al. ; 7115717 October 2006 Mori et al. ; 7132246 November 2006 Bergmann et al. ; 7153662 December 2006 Bergmann et al. ; 7157081 January 2007 Bergmann et al. ; 7598031 October 2009 Liew ; 7629116 December 2009 Ott ; 7892539 February 2011 Winoto et al. ; 8021836 September 2011 Kolopp-Sarda et al. ; 8465951 June 2013 Rao et al. ; 8507210 August 2013 Bergmann et al. ; 8563476 October 2013 Lillard, Jr. ; 8697370 April 2014 Kas et al. ; 8821876 September 2014 Ginsburg et al. ; 9034328 May 2015 Takahashi ; 9709565 July 2017 Eden et al. ; 9726668 August 2017 Oved ; 9850539 December 2017 Tsalik et al. ; 10209260 February 2019 Oved ; 10303846 May 2019 Eden et al. ; 10502739 December 2019 Oved et al. ; 10859574 December 2020 Oved et al. ; 2004/0038201 February 2004 Nau et al. ; 2004/0043379 March 2004 Hashimoto et al. ; 2004/0171013 September 2004 Lilius et al. ; 2005/0227223 October 2005 Miyawaki ; 2005/0233395 October 2005 Weiser et al. ; 2006/0052278 March 2006 Powell ; 2006/0099628 May 2006 Ching et al. ; 2006/0246495 November 2006 Garrett et al. ; 2007/0015172 January 2007 Zhang et al. ; 2007/0184460 August 2007 Ching et al. ; 2007/0231816 October 2007 Chaussabel et al. ; 2007/0281319 December 2007 Kolopp-Sarda et al. ; 2008/0020379 January 2008 Agan et al. ; 2008/0064113 March 2008 Goix et al. ; 2008/0171323 July 2008 Banchereau et al. ; 2009/0155180 June 2009 Jump et al. ; 2009/0203534 August 2009 Hossain et al. ; 2010/0028874 February 2010 Ramachandran et al. ; 2010/0068147 March 2010 Hibberd et al. ; 2010/0143372 June 2010 Yao et al. ; 2010/0297611 November 2010 Sambursky et al. ; 2011/0059858 March 2011 Kas et al. ; 2011/0117563 May 2011 Filipowicz et al. ; 2011/0166166 July 2011 Henkin ; 2011/0183856 July 2011 Agan et al. ; 2011/0275542 November 2011 Eden et al. ; 2011/0312534 December 2011 Kayser et al. ; 2013/0309168 November 2013 Ho ; 2014/0127827 May 2014 Kim et al. ; 2014/0206016 July 2014 Sanchez et al. ; 2014/0227324 August 2014 Robinson et al. ; 2015/0017630 January 2015 Oved et al. ; 2016/0153993 June 2016 Eden et al. ; 2017/0030909 February 2017 Oved et al. ; 2017/0234873 August 2017 Oved et al. ; 2017/0235871 August 2017 Eden et al. ; 2017/0269081 September 2017 Oved et al. ; 2018/0074057 March 2018 Eden et al. ; 2019/0011456 January 2019 Oved et al. ; 2019/0041388 February 2019 Oved et al. ; 2019/0085378 March 2019 Eden et al. ; 2019/0120837 April 2019 Eden ; 2019/0161813 May 2019 Oved et al. ; 2019/0237156 August 2019 Eden et al. ; 2019/0242894 August 2019 Oved et al. ; 2019/0242895 August 2019 Eden et al. ; 2019/0271709 September 2019 Eden et al. ; 2019/0339189 November 2019 Takeda et al. ; 2020/0124593 April 2020 Oved et al. ; 2020/0388347 December 2020 Eden et al. ; 2020/0393463 December 2020 Oved et al. ; 2020/0400668 December 2020 Eden et al. ; 1656378 August 2005 ; 101208602 June 2008 ; 101479389 July 2009 ; 101541976 September 2009 ; 101611314 December 2009 ; 101617056 December 2009 ; 101617230 December 2009 ; 101622364 January 2010 ; 101790687 July 2010 ; 102301002 December 2011 ; 103119444 May 2013 ; 104204803 December 2014 ; 1489416 December 2004 ; 2005-106694 April 2005 ; 2007-518062 July 2007 ; 2008-502908 January 2008 ; 2011-069696 April 2011 ; 10-2016-0072626 June 2016 ; WO 95/29404 November 1995 ; WO 99/33965 July 1999 ; WO 99/60171 November 1999 ; WO 01/14535 March 2001 ; WO 2004/108899 December 2004 ; WO2005/033327 April 2005 ; WO 2006/009702 January 2006 ; WO 2007/011412 January 2007 ; WO 2007/088355 August 2007 ; WO 2007/127801 November 2007 ; WO 2008/024642 February 2008 ; WO 2009/015821 February 2009 ; WO 2009/021521 February 2009 ; WO 2009/025743 February 2009 ; WO 2009/077864 June 2009 ; WO 2009/100907 August 2009 ; WO 2009/130176 October 2009 ; WO 2009/158521 December 2009 ; WO 2010/056637 May 2010 ; WO 2011/008349 January 2011 ; WO 2011/017682 February 2011 ; WO 2011/132086 October 2011 ; WO 2013/117746 August 2013 ; WO 2014/006408 January 2014 ; WO 2014/049255 April 2014 ; WO 2014/117873 August 2014 ; WO 2015/048098 April 2015 ; WO 2016/024278 February 2016 ; WO 2016/059636 April 2016 ; WO 2016/079219 May 2016 ; WO 2016/092554 June 2016 ; WO 2017/149547 September 2017 ; WO 2017/149548 September 2017 ; WO 2017/221255 December 2017 ; WO 2018/011795 January 2018 ; WO 2018/011796 January 2018 ; WO 2018/060998 April 2018 ; WO 2018/060999 April 2018
- Other References: Greenspan et al. 1999 (Defining epitopes: It's not as easy as it seems; Nature Biotechnology, 17:936-937) (Year: 1999). cited by examiner ; Rudikoff et al. 1982 (Single amino acid substitution altering antigen-binding specificity; PNAS, USA, 79(6): 1979-1983) (Year: 1982). cited by examiner ; Lloyd et al. 2009 (Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Engineering, Design & Selection 22(3):159-168) (Year: 2009). cited by examiner ; Official Action dated Feb. 3, 2020 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/355,984. (24 pages). cited by applicant ; Search Report and Opinion dated Dec. 10, 2019 From the Servico Publico Federal, Ministerio da Economia, Instituto National da Propriedade Industrial do Brasil Re. Application No. BR112017002884-0 and Its Translation Into English. (7 Pages). cited by applicant ; Supplementary European Search Report and the European Search Opinion dated Jan. 21, 2020 From the European Patent Office Re. Application No. 17827122.7. cited by applicant ; Applicant-Initiated Interview Summary dated Jul. 6, 2016 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/377,887. cited by applicant ; Applicant-Initiated Interview Summary dated Jul. 17, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/090,893. cited by applicant ; Applicant-Initiated Interview Summary dated Feb. 22, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/377,887. (3 Pages). cited by applicant ; Applicant-Initiated Interview Summary dated Oct. 26, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/237,728. (3 pages). cited by applicant ; Applicant-Initiated Interview Summary dated Jul. 30, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/641,400. (3 pages). cited by applicant ; Communication Pursuant to Article 94(3) EPC dated May 7, 2019 From the European Patent Office Re. Application No. 15831781.8. (3 Pages). cited by applicant ; Communication Pursuant to Article 94(3) EPC dated Dec. 9, 2016 From the European Patent Office Re. Application No. 13703112.6. (4 Pages). cited by applicant ; Communication Pursuant to Article 94(3) EPC dated Oct. 9, 2018 From the European Patent Office Re. Application No. 11748712.4. (8 Pages). cited by applicant ; Communication Pursuant to Article 94(3) EPC dated Jun. 17, 2016 From the European Patent Office Re. Application No. 11748712.4. cited by applicant ; Communication Pursuant to Article 94(3) EPC dated Jul. 31, 2019 From the European Patent Office Re. Application No. 18162713.4. (4 Pages). cited by applicant ; European Search Report and the European Search Opinion dated May 16, 2018 From the European Patent Office Re. Application No. 18162713.4. (7 Pages). cited by applicant ; Examination Report dated Oct. 6, 2017 From the Australian Government, IP Australia Re. Application No. 2013217935. (2 Pages). cited by applicant ; Examination Report dated May 29, 2019 From the Australian Government, IP Australia Re. Application No. 2018202302. (5 Pages). cited by applicant ; Examination Report Under Sections 12 & 13 of the Patents Act, 1970 and the Patents Rules, 2003 dated Oct. 21, 2019 From the Government of India, Intellectual Property India, Patents, Designs, Trade Marks, Geographical Indications Re. Application No. 9122/DELNP/2012 (5 Pages). cited by applicant ; Examination Report Under Sections 12 & 13 of the Patents Act, 1970 and the Patents Rules, 2003 dated Mar. 26, 2018 From the Government of India, Intellectual Property India, Patents, Designs, Trade Marks, Geographical Indications Re. Application No. 9122/DELNP/2012. (7 Pages). cited by applicant ; Examination Report Under Sections 12 & 13 of the Patents Act, 1970 and the Patents Rules, 2003 dated Nov. 30, 2018 From the Government of India, Intellectual Property India, Patents, Designs, Trade Marks, Geographical Indications Re. Application No. 1780/MUMNP/2014. (7 Pages). cited by applicant ; Examiner-Initiated Interview Summary dated Nov. 27, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/518,491. (2 pages). cited by applicant ; Hearing Notice Dated Jul. 16, 2019 From the Government of India, Patent Office, Intellectual Property Building Re. Application No. 1780/MUMNP/2014. (3 Pages). cited by applicant ; International Preliminary Report on Patentability dated Apr. 11, 2019 From the International Bureau of WIPO Re. Application No. PCT/IL2017/051088. (6 Pages). cited by applicant ; International Preliminary Report on Patentability dated Apr. 11, 2019 From the International Bureau of WIPO Re. Application No. PCT/IL2017/051089. (7 Pages). cited by applicant ; International Preliminary Report on Patentability dated Sep. 13, 2018 From the International Bureau of WIPO Re. Application No. PCT/IL2017/050270. (7 Pages). cited by applicant ; International Preliminary Report on Patentability dated Sep. 13, 2018 From the International Bureau of WIPO Re. Application No. PCT/IL2017/050271. (9 Pages). cited by applicant ; International Preliminary Report on Patentability dated Jun. 22, 2017 From the International Bureau of WIPO Re. Application No. PCT/IL2015/051201. (7 Pages). cited by applicant ; International Preliminary Report on Patentability dated Feb. 23, 2017 From the International Bureau of WIPO Re. Application No. PCT/IL2015/050823. (7 Pages). cited by applicant ; International Preliminary Report on Patentability dated Jan. 24, 2019 From the International Bureau of WIPO Re. Application No. PCT/IL2017/050780. (9 Pages). cited by applicant ; International Preliminary Report on Patentability dated Jan. 24, 2019 From the International Bureau of WIPO Re. Application No. PCT/IL2017/050781. (7 Pages). cited by applicant ; International Preliminary Report on Patentability dated Apr. 27, 2017 From the International Bureau of WIPO Re. Application No. PCT/IL2015/051024. (7 Pages). cited by applicant ; International Search Report and the Written Opinion dated Mar. 12, 2012 From the International Searching Authority Re. Application No. PCT/IB2011/001299. cited by applicant ; International Search Report and the Written Opinion dated Sep. 14, 2017 From the International Searching Authority Re. Application No. PCT/IL2017/050781. (12 Pages). cited by applicant ; International Search Report and the Written Opinion dated Jun. 15, 2017 From the International Searching Authority Re. Application No. PCT/IL2017/050270. (13 Pages). cited by applicant ; International Search Report and the Written Opinion dated Jun. 15, 2017 From the International Searching Authority Re. Application No. PCT/IL2017/050271. (16 Pages). cited by applicant ; International Search Report and the Written Opinion dated Sep. 18, 2017 From the International Searching Authority Re. Application No. PCT/IL2017/050780. (15 Pages). cited by applicant ; International Search Report and the Written Opinion dated Jan. 20, 2016 From the International Searching Authority Re. Application No. PCT/IL2015/051024. cited by applicant ; International Search Report and the Written Opinion dated Feb. 22, 2016 From the International Searching Authority Re. Application No. PCT/IL2015/051201. cited by applicant ; International Search Report and the Written Opinion dated Dec. 25, 2017 From the International Searching Authority Re. Application No. PCT/IL2017/051088. (9 Pages). cited by applicant ; International Search Report and the Written Opinion dated Dec. 28, 2017 From the International Searching Authority Re. Application No. PCT/IL2017/051089. (10 Pages). cited by applicant ; International Search Report and the Written Opinion dated Nov. 29, 2015 From the International Searching Authority Re. Application No. PCT/IL2015/050823. cited by applicant ; International Search Report dated Apr. 5, 2013 From the International Searching Authority Re. Application No. PCT/EP2013/052619. cited by applicant ; Notice of Non-Compliant Amendment dated Aug. 4, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/090,893. cited by applicant ; Notice of Reason for Rejection dated Nov. 12, 2019 From the Japan Patent Office Re. Application No. 2017-126712 and an English Summary. (3 Pages). cited by applicant ; Notice of Reason for Rejection dated Aug. 20, 2019 From the Japan Patent Office Re. Application No. 2017-507867 and Its Translation Into English. (5 Pages). cited by applicant ; Notice of Reasons for Rejection dated Nov. 1, 2016 From the Japan Patent Office Re. Application No. 2014-556086 and Its Translation Into English. (12 Pages). cited by applicant ; Notice of Reasons for Rejection dated Apr. 2, 2019 From the Japan Patent Office Re. Application No. 2017-126712 and Its Translation Into English. (8 Pages). cited by applicant ; Notice of Reasons for Rejection dated Jun. 19, 2018 From the Japan Patent Office Re. Application No. 2017-126712 and Its Translation Into English. (9 Pages). cited by applicant ; Notice on Office Action and the Search Report dated Feb. 25, 2015 From The State Intellectual Property Office of the People's Republic of China Re. Application No. 201180030792.1 and Its Translation Into English. cited by applicant ; Notification of Lack of Unity and Search Report dated Jan. 21, 2019 From the Federal Government Institution, Federal Institute of Industrial Property of the Federal Service for Intellectual Property, Patents and Trade Marks of the Russian Federation Re. Application No. 2017107750 and Its Translation of Office Action Into English. (12 Pages). cited by applicant ; Notification of Office Action and Search Report dated Mar. 4, 2016 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201380019055.0. cited by applicant ; Notification of Office Action and Search Report dated Jan. 11, 2019 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201580055946.0. (5 Pages). cited by applicant ; Notification of Office Action and Search Report dated Feb. 13, 2017 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201380019055.0 and Its Translation of Office Action Into English. (10 Pages). cited by applicant ; Notification of Office Action and Search Report dated Feb. 19, 2019 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201580075265.0 and A Summary of the Notification of Office Action Into English. (7 Pages). cited by applicant ; Notification of Office Action and Search Report dated Jun. 19, 2018 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201580075265.0 and its English Summary. (14 Pages). cited by applicant ; Notification of Office Action and Search Report dated Oct. 30, 2017 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201610817276.8. (10 Pages). cited by applicant ; Notification of Office Action dated Jul. 2, 2019 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201580075265.0. (3 Pages). cited by applicant ; Notification of Office Action dated Jul. 3, 2015 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201380019055.0. cited by applicant ; Notification of Office Action dated Jun. 3, 2019 From the China National Intellectual Property Administration Re. Application No. 201610817276.8 and Its Translation Into English. (10 Pages). cited by applicant ; Notification of Office Action dated Aug. 4, 2016 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201380019055.0 and Its Translation Into English. cited by applicant ; Notification of Office Action dated May 6, 2014 From The State Intellectual Property Office of the People's Republic of China Re. Application No. 201180030792.1 and Its Translation Into English. cited by applicant ; Notification of Office Action dated Jun. 20, 2018 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201580055946.0 and Its Summary in English. (5 Pages). cited by applicant ; Notification of Office Action dated Jan. 21, 2016 From The State Intellectual Property Office of the People's Republic of China Re. Application No. 201180030792.1 and Its Translation Into English. cited by applicant ; Notification of Office Action dated Aug. 22, 2019 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201580055946.0. (3 Pages). cited by applicant ; Notification of Office Action dated Aug. 25, 2017 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201380019055.0. (6 Pages). cited by applicant ; Notification of Office Action dated Aug. 28, 2015 From The State Intellectual Property Office of the People's Republic of China Re. Application No. 201180030792.1 and Its Translation Into English. cited by applicant ; Notification of Office Action dated Aug. 30, 2018 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201610817276.8 and Its Translation Into English. (22 Pages). cited by applicant ; Notification of Reexamination dated Jan. 12, 2018 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 2013800190and Its Machine Translation into English. cited by applicant ; Office Action dated Feb. 18, 2019 From the Israel Patent Office Re. Application No. 250585 and Its Translation Into English. (6 Pages). cited by applicant ; Office Action dated Nov. 28, 2019 From the Israel Patent Office Re. Application No. 254095 and its Translation into English. (7 Pages). cited by applicant ; Office Action dated Feb. 29, 2016 From the Israel Patent Office Re. Application No. 233998 and Its Translation Into English. cited by applicant ; Official Action dated Sep. 1, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/090,893. cited by applicant ; Official Action dated Apr. 4, 2016 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/090,893. cited by applicant ; Official Action dated Jan. 4, 2019 From the US Patent and Trademark Office Re. Application No. 15/713,722. (72 pages). cited by applicant ; Official Action dated Feb. 6, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/503,439. (63 pages). cited by applicant ; Official Action dated Nov. 7, 2016 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/090,893. (26 pages). cited by applicant ; Official Action dated Jun. 10, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/090,893. cited by applicant ; Official Action dated Apr. 12, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/518,491. (59 pages). cited by applicant ; Official Action dated Aug. 12, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/377,887. cited by applicant ; Official Action dated May 12, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/237,728. (27 pages). cited by applicant ; Official Action dated Apr. 13, 2016 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/377,887. cited by applicant ; Official Action dated Mar. 13, 2014 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/090,893. cited by applicant ; Official Action dated Apr. 15, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/237,728. (16 Pages). cited by applicant ; Official Action dated Dec. 15, 2016 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/377,887. (22 pages). cited by applicant ; Official Action dated May 15, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/237,728. (55 pages). cited by applicant ; Official Action dated Oct. 15, 2019 From the US Patent and Trademark Office Re. Application No. 151713,722. (57 Pages). cited by applicant ; Official Action dated Nov. 16, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/503,439. (41 pages). cited by applicant ; Official Action dated Sep. 16, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/355,984. (44 pages). cited by applicant ; Official Action dated Dec. 17, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/237,728. (39 pages). cited by applicant ; Official Action dated Nov. 18, 2016 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/237,728. (33 pages). cited by applicant ; Official Action dated Sep. 18, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/157,193. (30 pages). cited by applicant ; Official Action dated Apr. 23, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/157,193. (47 pages). cited by applicant ; Official Action dated Oct. 24, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/531,747. (37 Pages). cited by applicant ; Official Action dated Jan. 26, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/015,309. (45 pages). cited by applicant ; Official Action dated Mar. 26, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/090,893. cited by applicant ; Official Action dated Apr. 30, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/641,400. (62 pages). cited by applicant ; Official Action dated Mar. 30, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/531,747. (67 pages). cited by applicant ; Request for Examination dated Jun. 18, 2019 From the Federal Government Institution, Federal Institute of Industrial Property of the Federal Service for Intellectual Property, Patents and Trade Marks of the Russian Federation Re. Application No. 2017107750 and Its Translation of Office Action Into English. (11 Pages). cited by applicant ; Requisition by the Examiner Dated Oct. 4, 2019 From the Innovation, Science and Economic Development Canada, Canadian Intellectual Property Office Re. Application No. 2,863,819. (3 Pages). cited by applicant ; Requisition by the Examiner Dated Nov. 9, 2018 From the Innovation, Science and Economic Development Canada, Canadian Intellectual Property Office Re. Application No. 2,796,666. (3 Pages). cited by applicant ; Requisition by the Examiner Dated Jan. 18, 2018 From the Innovation, Science and Economic Development Canada, Canadian Intellectual Property Office Re. Application No. 2,796,666. (5 Pages). cited by applicant ; Requisition by the Examiner Dated Feb. 21, 2019 From the Innovation, Science and Economic Development Canada, Canadian Intellectual Property Office Re. Application No. 2,863,819. (8 Pages). cited by applicant ; Restriction Official Action dated Nov. 2, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/531,747. (9 pages). cited by applicant ; Restriction Official Action dated Dec. 5, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/081,906. (9 pages). cited by applicant ; Restriction Official Action dated Nov. 8, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/157,193. (5 pages). cited by applicant ; Restriction Official Action dated May 10, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/713,722. (6 Pages). cited by applicant ; Restriction Official Action dated Feb. 13, 2013 From the US Patent and Trademark Office Re. U.S. Appl. No. 13/090,893. cited by applicant ; Restriction Official Action dated May 15, 2015 From the US Patent and Trademark Office Re. U.S. Appl. No. 14/377,887. cited by applicant ; Restriction Official Action dated Nov. 29, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/238,582. (7 pages). cited by applicant ; Restriction Official Action dated Aug. 31, 2017 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/518,491. (6 pages). cited by applicant ; Search Report and Opinion dated Aug. 20, 2019 From the Servi?o Publico Federal, Ministerio da Economia, Institute Nacional da Propriedade Industrial do Brasil Re. Application No. BR112014 019733-4 and Its Summary in English. (4 Pages). cited by applicant ; Search Report dated May 6, 2014 From The State Intellectual Property Office of the People's Republic of China Re. Application No. 201180030792.1 and Its Translation Into English. cited by applicant ; Second Notice Of Allowance dated Dec. 12, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/641,400. (7 pages). cited by applicant ; Supplementary European Search Report and the European Search Opinion dated Mar. 15, 2018 From the European Patent Office Re. Application No. 15831781.8. (11 Pages). cited by applicant ; Supplementary European Search Report and the European Search Opinion dated Sep. 17, 2018 From the European Patent Office Re. Application No. 15868614.7. (18 Pages). cited by applicant ; Supplementary European Search Report and the European Search Opinion dated Sep. 30, 2019 From the European Patent Office Re. Application No. 17759388.6. (11 Pages). cited by applicant ; Supplementary Partial European Search Report and the European Provisional Opinion dated Jun. 1, 2018 From the European Patent Office Re. Application No. 15868614.7. (23 Pages). cited by applicant ; Supplementary Partial European Search Report and the European Provisional Opinion dated Oct. 24, 2019 From the European Patent Office Re. Application No. 17759389.4. (15 Pages). cited by applicant ; Translation Dated Sep. 4, 2017 of Notification of Office Action dated Aug. 25, 2017 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201380019055.0. cited by applicant ; Translation Dated Apr. 5, 2016 of Notification of Office Action dated Mar. 4, 2016 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201380019055.0. cited by applicant ; Translation Dated Jul. 10, 2019 of Notification of Office Action dated Jul. 2, 2019 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201580075265.0. (1 Page). cited by applicant ; Translation Dated Sep. 11, 2019 of Notification of Office Action dated Aug. 22, 2019 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201580055946.0. (1 Page). cited by applicant ; Translation Dated Mar. 20, 2019 of Notification of Office Action dated Feb. 19, 2019 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201580075265.0. (5 Pages). cited by applicant ; Translation Dated Sep. 21, 2015 of Office Action dated Jul. 3, 2015 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201380019055.0. cited by applicant ; Translation Dated Sep. 22, 2019 of Search Report and Opinion dated Aug. 20, 2019 From the Servi?o Publico Federal, Ministerio da Economia, Institute Nacional da Propriedade Industrial do Brasil Re. Application No. BR112014 019733-4 and Its Summary in English. (4 Pages). cited by applicant ; Translation Dated Jan. 30, 2019 of Notification of Office Action dated Jan. 11, 2019 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201580055946.0.(1 Page). cited by applicant ; Translation of Notification of Office Action and Search Report dated Oct. 30, 2017 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201610817276.8. (16 Pages). cited by applicant ; Translation of Reason for Rejection dated Nov. 21, 2019 of OA of Nov. 12, 2019 From the Japanese Patent Office Re. Application No. 2017-126712. (2 Pages). cited by applicant ; Alexander et al. “Staphylococcus aureus and Salmonella enterica Serovar Dublin Induce Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Expression by Normal Mouse and Hurnan Osteoblasts”, Infection and Immunity, 69(3): 1581-1586, Mar. 2001. cited by applicant ; Barnhart et al. “Changes in Cellular mRNA Stability, Splicing, and Polyadenylation Through HuR Protein Sequestration by A Cytoplasmic RNA Virus”, Cell Reports, XP055621573, 5(4): 909-917, Nov. 27, 2013. cited by applicant ; Biezeveld et al. “Sustained Activation of Neutrophils in the Course of Kawasaki Disease: An Association with Matrix Metalloproteinases”, Clinical & Experimental Immunology 141(1): 183-188, Jul. 2005. cited by applicant ; Boldrick et al. “Stereotyped and Specific Gene Expression Programs in Human Innate Immune Responses to Bacteria”, Proc. Natl. Acad. Sci. USA, PNAS, 99(2): 972-977, Jan. 22, 2002. cited by applicant ; Borjesson et al. “Insights Into Pathogen Immune Evasion Mechanisms: Anaplasma Phagocytophilum Fails to Induce An Apoptosis Differentiation Program in Human Neutrophils”, The Jurnal of Immunology, 174: 6364-6372, 2005. cited by applicant ; Boser et al. “A Training Algorithm for Optimal Margin Classifiers”, Proceedings of the 5th Annual ACM Workshop on Computational Learning Theory, COLT'92, Pittsburgh, PA, USA, Jul. 27-29, 1992, p. 144-152, Jul. 27, 1992. cited by applicant ; Calvano et al. “A Network-Based Analysis of Systemic Inflammation in Humans”, Nature, 437: 1032-1037, Oct. 13, 2005. cited by applicant ; Carrol et al. “The Diagnostic and Prognostic Accuracy of Five Markers of Serious Bacterial Infection in Malawian Children With Sign of Severe Infection”, PLoS ONE, 4(8): e6621-1-e6621-8. Aug. 2009. cited by applicant ; Chagan-Yasutan et al. “Persistent Elevation of Plasma Osteopontin Levels in HIV Patients Despite Highly Active Antiretroviral Therapy”, The Tohoku Journal of Experimental Medicine, 218(4): 285-292, Aug. 2009. cited by applicant ; Chaussabel et al. “Analysis of Significance Patterns Identifies Ubiquitous and Disease-Specific Gene-Expression Signatures in Patient Peripheral Blood Leukocytes”, Annals of the New York Academy of Sciences, 1062: 146-154, 2005. cited by applicant ; Chen et al. “Discordant Protein and mRNA Expression in Lung Adenocarcinomas”, Molecular & Cellular Proteomics: MCP, 1(4): 304-313, Apr. 2002. cited by applicant ; Chieux et al. “MxA Protein in Capillary Blood of Children With Viral Infections”, Journal of Medical Virology, 59: 547-551, 1999. cited by applicant ; Chieux et al. “The MxA Protein Levels in Whole Blood Lysates of Patients With Various Viral Infections”, Journal of Virological Methods, 70: 183-191, 1998. cited by applicant ; Consiglio et al. “BEAT: Bioinformatics Exon Array Tool to Store, Analyze and Visualize Affymetrix GeneChip Human Exon Array Data From Disease Experiments”, BMC Bioinformatics, XP021117755, 13(Suppl.4): S21-1-S21-14, Mar. 28, 2012. cited by applicant ; Corada et al. “Monoclonal Antibodies Directed to Different Regions of Vascular Endothelial Cadherin Extracellular Domain Affect Adhesion and Clustering of the Protein and Modulate Endothelial Permeability”, Blood, 97(6): 1679-1684, Mar. 15, 2001. cited by applicant ; Cowland et al. “Molerular Charaderization and Pattern of Tissue Expression of the Gene for Neutrophil Gelatinase-Associated Upocalin from Humans”, Genomics, 45:17-23,1997. cited by applicant ; Cristianini et al. “An Introduction to Support Vector Machines and Other Kernel-Based Learning Methods: Contents”, Cambridge University Press, 4 P., 2000. cited by applicant ; Crowe et al. “Quantitative Immunocytofluorographic Analysis of CD4 Surface Antigen Expression and HIV Infection of Human Peripheral Blood Monocyte/Macrophages”, Aids Research and Human Retroviruses, 3(2): 135-145, 1987. cited by applicant ; Cummins et al. “The TRAIL to Viral Pathogenesis: The Good, the Bad and the Ugly”, Current Molecular Medicine, XP055056835, 9(4): 495-505, May 1, 2009. cited by applicant ; Dirke et al. “TRAIL and DcR1 Expressions Are Differentially Regulated in the Pancreatic Islets of STZ-Versus CY-AppHed NOD Mice”, Experimental Diabetes Research, Article ID 625813, pp. 1-11, 2011. cited by applicant ; Duda et al. “Contents”, Pattern Classification, 2nd Ed., 11 P., 2001. cited by applicant ; Eberl et al. “A Rapid Crosstalk of Human gamma delta T Cells and Monocytes Drives the Acute Inflammation in Bacterial Infections”, PLOS Pathogens 5(2): 1-16, 2009. cited by applicant ; Falschlehner et al. “Following TRAIL'S Path in the Immune System”, Immunology, XP055056763, 127(2): 145-154, Jun. 1, 2009. Chapter ‘TRAIL in Viral and Bacterial Infections’. cited by applicant ; Feezor et al. “Molecular Characterization of the Acute Inflammatory Response to Infections With Gram-Negaitve Versus Gram-Positive Bacteria”, Infection and Immunity, 71(10): 5803-5813, Oct. 2003. cited by applicant ; Furey et al. “Support Vector Machine Classification and Validation of Cancer Tissue Samples Using Microarray Expression Data”, Bioinformatics, 16(10): 906-914, Oct. 2000. cited by applicant ; Halminen et al. “Expression of MxA Protein in Blood Lymphocytes Discriminates Between Viral and Bacterial Infections in Febrile Children”, Pediatric Research, 41(5): 647-650, May 1997. cited by applicant ; Hanley et al. “A Method of Comparing the Areas Under Receiver Operating Characteristics Curves Derived From the Same Cases”, Radiology. 148(3): 839-843, Sep. 1983. cited by applicant ; Hastie et al. “The Elements of Statistical Learning: Data Mining, Inference, and Prediction”, Springer Series in Statistics, 2nd Ed., p. 1-745, 2001. cited by applicant ; Hinson et al. “Viperin Is Highly Induced in Neutrophils and Macrophages during Acute and Chronic Lymphocytic Choriomeningitis Virus Infection”, The Journal of Immunology, 184:5723-5731, 2010. cited by applicant ; Hoffmann et al. “TRAIL Limits Excessive Host Immune Responses in Bacterial Meningitis”, JCI The Journal of Clinical Investigation. 117(7): 2004-2013, Jul. 2, 2007. cited by applicant ; Holland et al. “STAT3 Mutations in the Hyper-IgE Syndrome”, The New England Journal of Medicine, 357(16): 1608-1619, Oct. 18, 2007. cited by applicant ; Janols et al. “Lymphocyte and Monocyte Flow Cytometry Immunophenotyping as A Diagnostic Tool in Uncharacteristic Inflammatory Disorders”, BMC Infectious Diseases, XP002663504, 10(205): 1-9, 2010. Abstract. cited by applicant ; Jenner et al. “Insights Into Host Responses Against Pathogens From Transcriptional Profiling”, Nature Review Microbiology, 3: 281-294, Apr. 2005. cited by applicant ; Kaizer et al. “Gene Expression in Peripheral Blood Mononuclear Cells From Children With Diabetes”, The Journal of Clinical Endocrinology & Metabolism, 92(9): 3705-3711, 2007. cited by applicant ; Kawada et al. “Analysis of Gene-Expression Profiles by Oligonucleotide Microarray in Children With Influenza”, Journal of General Virology, 87: 1677-1683, 2006. cited by applicant ; Kichev et al. “Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAiL) Signaling and Cell Death in the Immature Central Nervous System after Hypoxia-Ischemia and Inflammation”, Journal of Biological Chemistry 289(13): 9430-9439, 2014. cited by applicant ; Kohavi et al. “Wrappers for Feature Subset Selection”, Artifical Intelligence, 97: 273-324, 1997. cited by applicant ; Kotelkin et al. “Respiratory Syncytial Virus Infections Sensitizes Cells to Apoptosis Mediated by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand”, Journal of Virology, XP055056816, 77(17): 9156-9172, Aug. 12, 2003. Fig.5B. cited by applicant ; Lampe et al. “Expression of the Interferon-Induced MxA Protein in Viral Encephalitis”, Neuropathology and Applied Neurobiology, 29(3): 273-279, May 27, 2003. cited by applicant ; Le Roux “Les Examens a Visee Etiologique Dans les Pneumopathies Communautaires de l'Enfant (Hors Imagerie) [Laboratory Investigations in Acute Lower Respiratory Tract Infections in Children]”, Archives de Pediatrie, XP002663501, 5(Suppl.1): 28S-32S, 1998. Abstract. cited by applicant ; Leibovici et al. “The Benefit of Appropriate Empirical Antibiotic Treatment in Patients with Bloodstream Infection”, Journal of Internal Medicine, 244(5): 379-386, Nov. 1, 1998. cited by applicant ; Liabeuf et al. “The Circulating Soluble TRAIL Is A Negative Marker for Inflammation Inversely Associated With the Mortality Risk in Chronic Kidney Disease Patients”, Nephrology Dialysis Transplantation, 25(8): 2596-2602, Advance Access Publication Feb. 26, 2010. Abstract, p. 2597, Right col. 2nd Para, Figs.2, 3. cited by applicant ; Liu et al. “Early Days: Genomics and Human Responses to Infection”, Current Opinion in Microbiology, 9: 312-319, Available Online May 6, 2006. cited by applicant ; Ludwig et al. “Tumor Necrosis Factor Related Apoptosis Inducing Ligand: A Novell Mechanism for Bacillus Calmette Guerin Induced Antitumor Activity” Cancer Research 64: 3386-3390,May 15, 2004. cited by applicant ; Malcolm et al. “Microarrays Analysis of Lipopolysaccharide-Treated Human Neutrophils”, American Journal of Physiology, Lung Cellular & Molecular Physiology, 284(4): L663-L670, First Published Dec. 20, 2002. cited by applicant ; Mount “Bioinformatics: Sequence and Genome Analysis”, Chaps.1-10: 1-564, 2001. cited by applicant ; Nakabayashi et al. “MxA-Based Recognition of Viral Illness in Febrile Children by A Whole Blood Assay”, Pediatric Research, 60(6): 770-774, 2006. cited by applicant ; Neu et al. “Expression of Tumor Necrosis Factor-Alpha-Related Apoptosis-Inducing Ligand and Its Proapoptotic Receptors Is Down-Regulated during Gastric Infection with Virulent cagA+/vacAs1+ Helicobacter pylori Strains”, The Journal of Infectious Diseases 191(4): 571-578, Feb. 15, 2005. cited by applicant ; Niederman “Biological Markers to Determine Eligibility in Trials for Community-Acquired Pneumonia: A Focus on Procalcitonin”, Clinical Infectious Diseases, XP002670357, 47(Suppl.3): S127-S132, Dec. 2008. cited by applicant ; Niessner et al. “Prognostic Value of Apoptosis Markers in Advanced Heart Failure Patients”, European Heart Journal, 30(7): 789-796, Published Online Feb. 4, 2009. Abstract, Table 2, Fig.2. cited by applicant ; Oda et al. “A Comprehensive Map of the Toll-Like Receptor Signaling Network”. Molecular Systems Biology, 2(2006.0015): 1-20, Apr. 18, 2006. cited by applicant ; Oved et al. “A Novel Host-Proteome Signature for Distinguishing Between Acute Bacterial and Viral Infections”, PLOS ONE, 10(3): e0120012-1-e120012-18, Mar. 18, 2015. Figs.3C, 4. cited by applicant ; Padlan “X-Ray Crystallography Of Antibodies”, Advances In Protein Chemistry, 49: 57-133; 1996. cited by applicant ; Paul et al. “Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis”, Antimicrobial Agents and Chemotherapy, 54(11): 4851-4863, Nov. 2010. cited by applicant ; Radom-Aizik et al. “Effects of 30 Min. of Aerobic Exercise on Gene Expression in Human Neutrophils”, Journal of Applied Physiology, 104: 236-243, 2008. cited by applicant ; Ramilo et al. “Gene Expression Patterns in Blood Leukocytes Discriminate Patients With Acute Infections”, Blood. 109(5): 2066-2077, Mar. 1, 2007. cited by applicant ; RayBiotech “Mouse L308 Array, Membrane [AAM-BLM-1]1-Series-308-Label-Based-Mouse-Cytok”, RayBiotech, XP055473187, Retrieved From the Internet, 7 P., May 7, 2018. cited by applicant ; Rosseau et al. “Comparative Transcriptional Profiling of the Lung Reveals Shared and Distinct Features of Streptococcus pneumoniae and Influenza A Virus Infection”, Immunology, 120: 380-391. 2006. cited by applicant ; Secchiero et al. “Potential Prognostic Significance of Decreased Serum Levels of TRAIL After Acute Myocardial Infarction”, PLoS ONE. XP055056988, 4(2): e4442-1-e4442-6, Feb. 16, 2009. Fig.1. cited by applicant ; Shimetani et al. “Levels of Three Inflammation Markers, C-Reactive Protein, Serum Amyloid A Protein and Procalcitonin, in the Serum and Cerebrospinal Fluid of Patients With Meningitis”, Scandinavian Journal of Clinical and Laboratory Investigation, XP008113027, 61(7): 567-574, 2001. Abstract. cited by applicant ; Singer et al. “The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)”, Journal of the American Medical Association, JAMA, 315(8): 801-810, Feb. 23, 2016. Box 3, Fig. cited by applicant ; Smith et al. “Quantitative Assessment of Human Whole Blood RNA as A Potential Biomarker for Infectious Disease”, Analyst, 132: 1200-1209, First Published Oct. 31, 2007. cited by applicant ; Sukumaran et al. “Early Transcriptional Response of Human Neutrophils to Anaplasma Phagocytophilum Infection”, Infection and Immunity, 73(12): 8089-8099, Dec. 1, 2005. cited by applicant ; Sullivan Pepe et al. “Combining Diagnostic Test Results to Increase Accuracy”, Biostatistics, XP055033234, 1(2): 123-140, Jun. 1, 2000. Abstract, Section 2.4. cited by applicant ; Tang et al. “Gene-Expression Profiling of Gram-Positive and Gram-Negative Sepsis in Critically Ill Patients”, Critical Care Medicine, 36(4): 1125-1128, 2008. cited by applicant ; Tang et al. “Hypoxic Preconditioning Enhances the Benefit of Cardiac Progenitor Cell Therapy for Treatment of Myocardial Infarction by Inducing CXCR4 Expression”, Circulation Research, XP055473182, 104(10): 1209-1216, May 22, 2009. Online Table 1. cited by applicant ; Tang et al. “The Use of Gene-Expression Profiling to Identify Candidate Genes in Human Sepsis”, American Journal of Respiratory and Critical Care Medicine, 176: 676-684, Originally Published Jun. 15, 2007. cited by applicant ; Thivierge et al. “Eukaryotic Elongation Factor 1A Interacts With Turnip Mosaic Virus RNA-Dependent RNA Polymerase and VPg-Pro in Virus-Induced Vesicles”, Virology, XP002663503, 377(1): 216-225, Jul. 2008. cited by applicant ; Tian et al. “Soluble Tumor Necrosis Factor Related Apoptosis Inducing Ligand Level as A Predictor of Severity of Sepsis and the Risk of Mortality in Septic Patients”, PLOS One, 8(12): e82204-1-e82204-5, Dec. 12, 2013. cited by applicant ; Tisato et al. “Low Circulating TRAIL Levels Are Associated with Increase of Resistin and Lipocalin-2/ngal Adipokines in Postmenopausal Women”, Mediators of Inflammation, Article ID 5356020, 8 Pages, 2017. cited by applicant ; Torkkola “Feature Extraction by Non-Parametric Mutual Information Maximization”, Journal of Machine Learning Research, 3: 1415-1438, Mar. 2003. cited by applicant ; Tsuji “TRAILing Gastrointestinal Pathogenesis”, Journal of Gastroenterology and Hepatology, 18(7): 753-755, Published Online Jun. 10, 2003. cited by applicant ; Tworoger et al. “Collection, Processing, and Storage of Biological Samples in Epidemiologic Studies: Sex Hormones, Carotenoids, Inflammatory Markers, and Proteomics as Examples”, Cancer Epidemiol Biomarkers and Prevention, 15(9): 1578-1581, Sep. 2006. cited by applicant ; UCSC “UCSC Browser on Human Feb. 2009 (GRCh37/hg19) Assembly: Showing Location of Probes on the Affymetrix ExonChip Binding to Exons of ANKRD22”, UCSC Browser, XP055621243, Retrieved From the Internet, 7 P., Jan. 2009. cited by applicant ; UCSC “UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly: Showing Location of Probes on the Affymetrix ExonChip Binding to Exons of AIM2”, UCSC Browser, XP055621240, Retrieved From the Interent, 8 P., Jan. 2009. cited by applicant ; Vapnik “Statistical Learning Theory”, Adaptive and Learning Systems for Signal Processing, Communications, and Control, p. 1-732, 1998.—Part I. cited by applicant ; Vapnik “Statistical Learning Theory”, Adaptive and Learning Systems for Signal Processing, Communications, and Control, p. 1-732, 1998.—Part II. cited by applicant ; Vapnik “Statistical Learning Theory”, Adaptive and Learning Systems for Signal Processing, Communications, and Control, p. 1-732, 1998.—Part III. cited by applicant ; Vapnik “Statistical Learning Theory”, Adaptive and Learning Systems for Signal Processing, Communications, and Control, p. 1-732, 1998.—Part IV. cited by applicant ; Vogel et al. “Sequence Signatures and mRNA Concentration Can Explain Two-Thirds of Protein Abundance Variation in A Human Cell Line”, Molecular Systems Biology, 6(Art.400): 1-9, Published Online Aug. 24, 2010. cited by applicant ; Wang et al. “Rotavirus Infection Alters Peripheral T-Cell Homeostasis in Children With Acute Diarrhea”, Journal of Virology, 81(8): 3904-3912, Apr. 2007. cited by applicant ; Whiteside et al. “Role of Human Natural Killer Cells in Health and Disease”, Clinical and Diagnostic Laboratory Immunology, 1(2): 125-133, Mar. 31, 1994. cited by applicant ; Xu et al. “Lipocalins as Biochemical Markers of Disease”, Biochimica et Biophysica Acta, XP002376345, 1482(1): 298-307, Oct. 18, 2000. cited by applicant ; Yamaji et al. “Significance of Eukaryotic Translation Elongation Factor 1A in Tobacco Mosaic Virus Infection”, Archives of Virology, XP002663502, 155(2): 263-268, Feb. 2010. Abstract. cited by applicant ; Yeung et al. “Serum Cytokines in Differentiating Between Viral and Bacterial Enterocolitis”, Annals of Tropical Paediatrics, 24(4): 337-343. Published Online Jul. 18, 2013. cited by applicant ; Zaas et al. “A Host-Based RT-PCR Gene Expression Signature to Identify Acute Respiratory Viral Infection”, Science Translational Medicine, 5(203): 203ra126-1-203ra126-19, Sep. 18, 2013. cited by applicant ; Zaas et al. “Gene Expression Signatures Diagnose Influenza and Other Symptomatic Respiratory Viral Infections in Humans”, Cell Host & Microbe, XP002670360, 6(3): 207-217, Sep. 17, 2009. Abstract, p. 212,1-h col. p. 213, 1-h col. Fig.4. cited by applicant ; Zaas et al. “The Current Epidemiology and Clinical Decisions Surrounding Acute Respiratory Infections”, Trends in Molecular Medicine, XP055522333, 20(10): 579-588, Published Online Sep. 5, 2014. cited by applicant ; Zhu et al. “Use of Differential Display Analysis to Assess the Effect of Human Cytomegalovirus Infection on the Accumulation of Cellular RNAs: Induction of Interferon-Responsive RNAs”, Proc. Natl. Acad. Sci. USA, XP002088235, 94(25): 13985-13990, Dec. 9, 1997. Abstract, Fig.2. cited by applicant ; Zilliox et al. “Gene Expression Changes in Peripheral Blood Mononuclear Cells During Measles Virus Infection”. Clinical and Vaccine Immunology, 14(7): 918-923, Jul. 2007. cited by applicant ; Supplementary European Search Report and the European Search Opinion dated Jan. 28, 2020 From the European Patent Office Re. Application No. 17759389.4. (11 Pages). cited by applicant ; Advisory Action Before the Filing of An Appeal Brief dated Dec. 23, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/157,193. (3 pages). cited by applicant ; Applicant-Initiated Interview Summary dated Feb. 10, 2020 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/157,193. (3 pages). cited by applicant ; Supplementary European Search Report and the European Search Opinion dated Feb. 18, 2020 From the European Patent Office Re. Application No. 17827121.9. (5 Pages). cited by applicant ; Communication Pursuant to Article 94(3) EPC dated Jun. 4, 2020 From the European Patent Office Re. Application No. 17759388.6. (3 Pages). cited by applicant ; Supplementary European Search Report and the European Search Opinion dated May 18, 2020 From the European Patent Office Re. Application No. 17855164.4. (13 Pages). cited by applicant ; Shommu et al. “Metabolomic and Inflammatory Mediator Based Biomarker Profiling as A Potential Novel Method to Aid Pediatric Appendicitis Identification”, PLOS ONE, XP055692841, 13(3): e0193563-1-e0193563-13, Mar. 12, 2018. cited by applicant ; Partial European Search Report and Provisional Opinion dated Jun. 25, 2020 From the European Search Report Re. Application No. 20164056.2. (11 Pages). cited by applicant ; Pepe et al. “Combining Diagnostic Test Results to Increase Accuracy”, Biostatistics, XP055033234, 1(2): 123-140, Jun. 2000. cited by applicant ; Office Action dated Jul. 30, 2020 From the Israel Patent Office Re. Application No. 261529 and Its Translation Into English. (5 Pages). cited by applicant ; Office Action dated Jul. 30, 2020 From the Israel Patent Office Re. Application No. 261530 and Its Translation Into English. (5 Pages). cited by applicant ; Restriction Official Action dated Jul. 30, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/081,906. (7 pages). cited by applicant ; Notification of Office Action and Search Report dated Jul. 28, 2020 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201810781584.9 and Its Translation of Office Action Into English. cited by applicant ; Bai et al. “A New Early Diagnostic Marker for Inflammatory Diseases—sTREM-1”, International Journal of Pathology and Clinical Medicine, 27(1): 73-76, Feb. 2007. cited by applicant ; Cai et al. “The Study on the Relationship Between PCT and CRP in Infective Diseases”, Journal al of Qiqihar University of Medicine, 32(5): 696-697, 2011. cited by applicant ; Ju et al. “Research Progress of Some Inflammatory Markers in Infectious Diseases”, Chinese Journal of Practical Internal Medicine, 30(Suppl.1): 80-81, Jun. 2010. cited by applicant ; Communication Pursuant to Article 94(3) EPC dated Mar. 25, 2020 From the European Patent Office Re. Application No. 18162713.4. (5 Pages). cited by applicant ; Communication Pursuant to Article 94(3) EPC dated Mar. 27, 2020 From the European Patent Office Re. Application No. 15868614.7. (6 Pages). cited by applicant ; Official Action dated Mar. 31, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 15/531,747. (21 pages). cited by applicant ; Restriction Official Action dated Apr. 2, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/081,069. (7 pages). cited by applicant ; Communication Pursuant to Article 94(3) EPC dated May 25, 2020 From the European Patent Office Re. Application No. 11748712.4. (7 Pages). cited by applicant ; Official Action dated May 15, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/238,582. (92 pages). cited by applicant ; Official Action dated May 7, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/157,193. (23 pages). cited by applicant ; Supplementary European Search Report and the European Search Opinion dated May 4, 2020 From the European Patent Office Re. Application No. 17855163.6. (9 Pages). cited by applicant ; Ali et al. “Reliability of Serum Procalcitonin Concentrations for the Diagnosis of Sepsis in Neonates”, Egypt Journal of Immunology, 15(1): 75-84, 2008. Abstract only. cited by applicant ; Becker et al. “Procalcitonin in Sepsis and Systemic Inflammation: a Harmful Biomarker and a Therapeutic Target”, British Journal of Pharmacology, 159: 253-264, 2010. cited by applicant ; Forde et al. “The Beneficial Pleiotropic Effects of Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Within the Vasculature: A Review of the Evidence”, Atherosclerosis, XP029468976, 247: 87-96, Available Online Feb. 9, 2016. cited by applicant ; Herzig et al. “The Role of CXCL10 in the Pathogenesis of Experimental Septic Shock”, Critical Care, 18(3): 1-18, 2014. cited by applicant ; Ng et al. “IP-10 Is an Early Diagnostic Marker for Identification of Late-Onset Bacterial Infection in Preterm Infants”, Pediatric Research, 61(1): 93-98. 2007. cited by applicant ; Povoa et al. “C-Reactive Protein, an Early Marker of Community-Acquired Sepsis Resolution: a Multi-Center Prospective Observational Study”, Critical Care, 15(4): 1-10, 2011. cited by applicant ; Sasaki et al. “Differentiating Between Bacterial and Viral Infection by Measuring Both C-Reactive Protein and 2′-5′-Oligoadenylate Svnthetase as Inflammatory Markers”, Journal of Infection and Chemotherapy, XP055696216, 8(1): 76-80, Mar. 2002. cited by applicant ; Official Action dated Mar. 5, 2020 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/713,722. (24 pages). cited by applicant ; Communication Pursuant to Article 94(3) EPC dated Mar. 17, 2021 From the European Patent Office Re. Application No. 15868614.7. (5 Pages). cited by applicant ; Notification of Office Action dated Mar. 5, 2021 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201810781584.9 and Its Translation of Office Action Into English. (13 Pages). cited by applicant ; Official Action dated Mar. 10, 2021 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/081,906. (127 Pages). cited by applicant ; Shair et al. “Epstein-Barr Virus Latent Membrane Protein-1 Effects on Junctional Plakoglobin and Induction of a Cadherin Switch”, Cancer Research, Cell, Tumor, and Stem Cell Biology, 69(14): 5734-5742, Jul. 15, 2009. cited by applicant ; Official Action dated Mar. 9, 2021 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/316,631. (121 Pages). cited by applicant ; Patent Examination Report dated Feb. 8, 2021 From the Australian Government, IP Australia Re. Application No. 2015302870. (4 Pages). cited by applicant ; Notice of Reasons for Rejection dated Apr. 20, 2021 From the Japan Patent Office Re. Application No. 2020-021606 and Its Translation Into English. (9 Pages). cited by applicant ; Official Action dated May 5, 2021 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/336,528. (108 Pages). cited by applicant ; Second Notice of Allowance dated May 12, 2021 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/355,984. (32 Pages). cited by applicant ; Brost et al. “Differential Expression of the TRAIL/TRAIL-reccptor System in Patients with Inflammatory Bowel Disease”, Pathology—Research and Practice, 206(1):43-50, Jan. 15, 2010. cited by applicant ; Notification of Office Action and Search Report dated Feb. 20, 2021 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201780014568.0 and Its Translation Into English. (22 Pages). cited by applicant ; Restriction Official Action dated Mar. 29, 2021 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/081,069. (8 Pages). cited by applicant ; Communication Pursuant to Article 94(3) EPC dated Nov. 12, 2020 From the European Patent Office Re. Application No. 17759389.4. (6 Page). cited by applicant ; Official Action dated Nov. 23, 2020 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/355,984. (9 pages). cited by applicant ; Official Action dated Dec. 30, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/334,033. (112 pages). cited by applicant ; Requisition by the Examiner Dated Dec. 7, 2020 From the Innovation, Science and Economic Development Canada, Canadian Intellectual Property Office Re. Application No. 2,863,819. (4 Pages). cited by applicant ; Restriction Official Action dated Dec. 9, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/336,528. (7 pages). cited by applicant ; Bone et al. “Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis”, Chest, 101(6): 1644-1655, 1992. cited by applicant ; Kang et al. “Low serum TNF-Related Apoptosis-Inducing Ligand (TRAIL) Levels Are Associated with Acute Ischemic Stroke Severity”, Atherosclerosis, 240: 228-233, 2015. cited by applicant ; Michowitz et al. “The Involvement of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand(TRAIL) in Atherosclerosis. ”, Journal of the American College of Cardiology, 45(7): 1018-1024, 2005. cited by applicant ; Osmancik et al. “Prognostic Value of TNF-Related Apoptosis Inducing Ligand (TRAIL) in Acute Coronary Syndrome Patients”, PLoS One, 8(2): e53860, 2013. cited by applicant ; Volpato et al. “Association of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand with Total and Cardiovascular Mortality in Older Adults”, Atherosclerosis, 215:452-458,2011. cited by applicant ; Communication Pursuant to Article 94(3) EPC dated Aug. 18, 2020 From the European Patent Office Re. Application No. 11748712.4. (3 Pages). cited by applicant ; Communication Pursuant to Article 94(3) EPC dated Sep. 25, 2020 From the European Patent Office Re. Application No. 17827122.7. (5 Pages). cited by applicant ; European Search Report and the European Search Opinion dated Sep. 28, 2020 From the European Patent Office Re. Application No. 20164056.2. (10 Pages). cited by applicant ; Interview Summary dated Oct. 14, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/081,906. (3 pages). cited by applicant ; Official Action dated Nov. 4, 2020 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/238,582. (37 Pages). cited by applicant ; Official Action dated Oct. 20, 2020 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/081,069. (112 Pages). cited by applicant ; Restriction Official Action dated Sep. 10, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/316,631. (6 pages). cited by applicant ; ThermoFisher Scientific “Interferon Alpha Inducible Protein 27: IF127”, ThermoFisher Scientific, Product Details, 2 P., 2020. cited by applicant ; ThermoFisher Scientific “Interferon Induced Protein 44 Like: IF144L”, ThermoFisher Scientific, Product Details, 2 P., 2020. cited by applicant ; ThermoFisher Scientific “TaqMan Gene Expression Assay Solutions: Proven 5′ Nuclease-Based Real-Time PCR Chemistry”, Thermo Fisher Scientific, Applied Biosystems, 11 P., 2015. cited by applicant ; Zaas et al. Supplementary Materials for “A Host-Based RT-PCR Gene Expression Signature to Identify Acute Respiratory Viral Infection”, Science Translational Medicine, 5(203): 203ra126-1-203ra126-21, Sep. 18, 2013. cited by applicant ; Examination Report Under Sections 12 & 13 of the Patents Act, 1970 and the Patents Rules, 2003 dated Mar. 31, 2021 From the Government of India, Intellectual Property India, Patents, Designs, Trade Marks, Geographical Indications, The Patent Office Re. Application No. 201727005513. (7 Pages). cited by applicant ; Notice of Allowance dated Apr. 19, 2021 from the US Patent and Trademark Office Re. U.S. Appl. No. 16/238,582. (22 pages). cited by applicant ; Bloos et al. “Rapid Diagnosis of Sepsis”; Virulence, 5(1): 154-160, 2014. cited by applicant ; Henriquez-Camacho et al. “Biomarkers for Sepsis”; BioMed Research International, 547818: 6 pages. 2014. cited by applicant ; Communication Pursuant to Article 94(3) EPC dated Jun. 2, 2021 From the European Patent Office Re. Application No. 17827121.9. (5 Pages). cited by applicant ; Final Official Action dated Jun. 15, 2021 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/334,033. (36 Pages). cited by applicant ; Notice of Reason(s) for Rejection dated Jun. 15, 2021 From the Japan Patent Office Re. Application No. 2020-109710 and Its Translation Into English. (12 Pages). cited by applicant
- Primary Examiner: Lyons, Mary Maille
|
